Bristol-Myers Squibb vs McKesson

Bristol-Myers Squibb (BMY), health care, and McKesson (MCK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Bristol-Myers Squibb and McKesson are valued at about the same: $124.7B and $127B. Bristol-Myers Squibb trades at 13.5 times earnings and McKesson at 28.4. Over the past year Bristol-Myers Squibb's share price has moved +33.7% and McKesson's +28.4%.

Key facts

Bristol-Myers Squibb market value
$124.7B
McKesson market value
$127B
Bristol-Myers Squibb P/E
13.5
McKesson P/E
28.4
Bristol-Myers Squibb revenue
$48.2BFY to 2025-12-31
McKesson revenue
$403.4BFY to 2026-03-31
Superinvestors holding both
1

Market values as of .

Bristol-Myers Squibb vs McKesson: every measure side by side
Measure Bristol-Myers Squibb McKesson
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312026-03-31
Size
Market cap$124.7Blower$127Bhigher
Revenue$48.2Blower$403.4Bhigher
Earnings$7.1Bhigher$4.8Blower
Employees32,500lower41,600higher
Total assets$90Bhigher$82.3Blower
Valuation
P/E13.5lower28.4higher
P/S2.6higher0.3lower
P/B5.3—
Dividend yield4.00%higher0.31%lower
Profitability
Operating margin—1.54%
Balance sheet
Net assets$18.5Bhigher-$2.2Blower
Total liabilities$71.5Blower$83.2Bhigher
Total debt$45.1Bhigher$6.5Blower
Cash on hand$10.2Bhigher$4Blower
Price change
Today-3.08%lower-0.48%higher
1 year+33.7%higher+28.4%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Bristol-Myers Squibb / McKesson). Who owns BMY · Who owns MCK

Further comparisons

Learn

Questions and answers

Which is bigger, Bristol-Myers Squibb or McKesson?

By market value, McKesson is the larger: $127B against $124.7B for Bristol-Myers Squibb. By revenue in its latest fiscal year, McKesson is the larger: $403.4B against $48.2B for Bristol-Myers Squibb.

Which has the higher P/E ratio?

McKesson: 28.4, against 13.5 for Bristol-Myers Squibb. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher dividend yield?

Bristol-Myers Squibb: 4.00%, against 0.31% for McKesson. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Bristol-Myers Squibb: $45.1B, against $6.5B for McKesson. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Bristol-Myers Squibb and McKesson?

In their latest 13F filings, Cliff Asness holds both.

Cite this page

Funkfolio, “Bristol-Myers Squibb vs McKesson”, data as of 17 November 2026. https://funkfolio.com/compare/bmy-vs-mck

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.